Oncologists in this study reported that they use testing 68% of the time to identify cancers that have certain types of biomarkers, called tyrosine receptor kinase (TRK) fusions, prior to patients beginning systemic treatment such as chemotherapy.

The majority of oncologists (96%) reported no difficulties interpreting TRK fusion cancer test reports and 89% indicated that they reviewed TRK fusion cancer testing guidelines regularly.

However, less than half (46%) reported that they include tropomyosin receptor kinase inhibitors (TRKis), a targeted therapy for TRK fusion cancers, after a positive TRK fusion cancer test result.